NextConsensus
Start with one claim

NICE appraisal calendar 2026: expected dates with registered forecasts

This calendar lists the NICE technology appraisals NextConsensus has registered a forecast on, by expected publication month. Each row gives NICE's title for the appraisal, the project ID, the committee and the registered probability. Follow a row to its record for the terms that settle it.

A row's probability is the estimate that NICE publishes the appraisal's final guidance by the expected date, whatever the guidance recommends. It was frozen at registration. A revised date with nothing published, a pause, a suspension or a termination resolves the record NO.

Each date is the one the appraisal's in-development page on nice.org.uk showed at the record's cutoff; a later revision does not move it. The NICE scheduled-dates guide covers what the date commits NICE to and what each outcome means for a plan.

NICE guidance by scheduled date: 11 registered · 11 unresolved · 0 resolved. Registry snapshot 2026-10-06.

Expected NICE publication dates in October 2026

Expected date Appraisal Project ID Committee Registered probability
Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatmentsFF-016 ID6586 Technology Appraisal Committee 45%Unresolved

Expected NICE publication dates in November 2026

Expected date Appraisal Project ID Committee Registered probability
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatmentFF-017 ID6425 Technology Appraisal Committee 50%Unresolved
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinomaFF-019 ID6239 Technology Appraisal Committee 45%Unresolved
Zuranolone for treating postnatal depressionFF-022 ID6431 Technology Appraisal Committee 50%Unresolved
Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosaFF-014 ID3959 Highly Specialised Technologies Evaluation Committee 35%Unresolved
Efgartigimod for treating chronic inflammatory demyelinating polyneuropathyFF-015 ID6409 Highly Specialised Technologies Evaluation Committee 45%Unresolved
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630)FF-018 ID6292 Technology Appraisal Committee 55%Unresolved
Orforglipron for managing overweight and obesityFF-020 ID6516 Technology Appraisal Committee 5%Unresolved
Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatmentsFF-021 ID6363 Technology Appraisal Committee 50%Unresolved
Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemiaFF-028 ID6519 Technology Appraisal Committee C 40%Unresolved
Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and overFF-029 ID6497 Highly Specialised Technologies Evaluation Committee 35%Unresolved

Technology appraisal (NICE): offered on judgment, with no calibration figure until 15 in the class have resolved.

Other registered dates

Bring the appraisal and your deadline

Name the appraisal, its expected publication date, and the decision your team makes on it.

Start with one claim